RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Thanks Neuro. Btw, with the Biovail/Valeant merger, just wondering how likely you see RD/Ampakines being spun off, compared to some of Biovail's other recently acquired/partnered CNS programs like Alexa's AZ-004?

Thanks.


From your NI website -

>>> 3) Biovail Merger with Valeant Pharma: In theory, growing the company via this merger could fund development for Biovail's CNS pipeline. But given the fact that Valeant has been putting its own resources into other areas, like dermatology and emerging markets; exited CNS after its successfully licensed retigabine to GSK; and that it is the Valeant CEO, Michael Pearson, who will oversee daily operations as CEO of the merged company, there is reason to worry for Biovail's CNS pipeline strategy. We would not be surprised to see an inlicensed program dropped, cheering only the short-sighted denizens of Wall Street, who believe that addition is best achieved by subtraction. <<<


Also, concerning the recent M J Fox Foundation funding for high impact/Parkinson's research, do you see this indicating that Cortex will be more or less likely to do a high impact pharma deal/R+D collaboration in the near/mid term? The MJ Fox research is in animal models, so presumably Cortex won't be tying up the lead high impact compound, so perhaps the MJ Fox funded program won't interfere with Cortex's plans for a high impact pharma deal?

Thanks.